CORAL GABLES, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) CPRa commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for patients with rare diseases, today announced that Patrick J. McEnany, Catalyst’s Chairman and CEO, along with other members of the management team, are doing so will attend HC Wainwright’s hybrid in-person and virtual 24th Annual Global Investment Conference, taking place September 12-14, 2022.
The company’s on-demand presentation will be available to registered attendees through the HC Wainwright conference portal beginning Monday, September 12, 2022 at 7:00 a.m. Eastern Time. A copy of the presentation will be available on the Investor Relations section of the Company’s website at www.catalystpharma.com. The Catalyst management team will participate in one-on-one meetings during scheduled virtual meeting times.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the in-licensing, development and commercialization of novel medicines for patients with rare diseases. With an exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst’s new drug application for FIRDAPSE® (amifampridine) tablets 10 mg for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (“LEMS”) was approved by the U.S. Food & Drug Administration (“FDA”) in 2018, and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. In addition, Canada’s national healthcare regulator, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients with LEMS in Canada.
More information about the company can be found at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Foresighted…
